Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies that improve patient health outcomes, announced today that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.
Related news for (MRZM)
- Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
- Marizyme CEO Delivers Business Update
- InvestmentPitch Media Video Features Marizyme’s CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device
- The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News